-

Kurin, Inc. Announces Launch of Its Proprietary Push-button Needle System

SAN DIEGO--(BUSINESS WIRE)--Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets announced that they have commenced the commercial launch of their push-button needle, to be used as part of Kurin blood culture sets. The Advance Safety Needle System was tested in 2021 and is now being sold into accounts using Kurin.

“We are proud to commercialize the Advance Safety Needle, as there has been market demand for alternatives and improvements in this space,” said Bob Rogers, CEO of Kurin, Inc. “We are pleased with our field trials performed over the past several months. In addition to the positive feedback that we received, our testing shows improved performance characteristics compared to traditional, retraction-oriented products. The development of the Advance Needle is an important milestone for Kurin, providing us a more reliable supply of product, better cost control, the opportunity to offer improved benefits over current needles, and creates new strategic opportunities in which we are already engaged.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection.

About Kurin, Inc.

Kurin, Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. Kurin, manufactured in San Diego, CA, has received FDA 510(k) market clearance. For more information about Kurin, visit the website at www.kurin.com.

Contacts

Matt Heindel
Kurin, Inc.
858-752-9514
mattheindel@kurin.com

Kurin, Inc.


Release Summary
Kurin, Inc. announces the launch of its proprietary push-button needle system for Kurin(R) blood culture collection sets.
Release Versions

Contacts

Matt Heindel
Kurin, Inc.
858-752-9514
mattheindel@kurin.com

More News From Kurin, Inc.

Kurin and Crouse Hospital: A Transformative Partnership in Reducing Contaminated Blood Cultures

SAN DIEGO--(BUSINESS WIRE)--The synergy between Kurin's technology and Crouse Hospital's dedication to excellence sets a new standard for managing contaminated blood cultures....

Kurin Works with The Ohio State University Wexner Medical Center on Patient Safety and Increased Access to High Quality Healthcare

SAN DIEGO--(BUSINESS WIRE)--Kurin, Inc. and The Ohio State University Wexner Medical Center are working together to reduce contaminated blood cultures....

Final Judgment Entered in Kurin’s Favor over Magnolia Medical

SAN DIEGO--(BUSINESS WIRE)--U.S. District Court for the District of Delaware entered Final Judgment that Kurin Inc. does not infringe Magnolia Medical, Inc.’s patent...
Back to Newsroom